Taylor et al. designed antisense oligonucleotides to modulate the alternative Bcl-X pre-mRNA splicing process, leading to elevated expression of Bcl-XS and increased susceptibility of lung cancer cells to therapeutic treatment [46]. This evidence concerns the gene BCL2L1 and lung cancer.